|
The following stocks are the leading risers and fallers on AIM on Monday. ---------- AIM - WINNERS ---------- Pebble Beach Systems Group PLC, up 12% at 18.5 pence, 12-month range 6p-21.5p. Surrey, England-based software company has won a £1.3 million contract over its five-year term with ‘a Tier 1, US-based streaming company’ via a US-based partner. Says there is scope for significant further revenues as the relationship grows and extends. Says implementation of its technology, which automates the delivery of video and audio material, has already started. Pebble Beach will be providing support and maintenance services over the contract term. ‘The adoption of [Pebble Beach’s] software solution marks an important step in the expansion of the Tier 1 streaming company’s playout capabilities,’ the firm says. ---------- Cambridge Cognition Holdings PLC, up 10% at 43.5p, 12-month range 25p-45.5p. The Cambridge, England-based brain health software provider announces a commercialisation agreement with Indian brain health company Ivory for Cambridge Cognition’s CANTAB Pathway. Says Ivory will deploy CANTAB Pathway across both professional healthcare and consumer health segments in India, ‘leveraging Ivory’s rapidly scaling brain health platform and distribution network.’ ‘India represents a major opportunity, with a significant unmet need for earlier identification of cognitive impairment,’ comments Cambridge Cognition Chief Executive Rob Baker. ‘As health-conscious, tech-enabled populations grow, demand for proactive brain health tools is increasing rapidly...We are excited to partner with [Ivory] to expand access to CANTAB Pathway in India.’ ---------- AIM - LOSERS ---------- SkinBioTherapeutics PLC, down 42% at 7.15p, 12-month range 7.15p-26.1p. The Newcastle Upon Tyne, England-based life science company has recently ‘been urgently conducting an investigation’ amid the suspension and, on Friday, the subsequent resignation of former chief executive Stuart Ashman. SkinBioTherapeutics says on Monday that it now has reason to believe that Ashman misrepresented material information to the board, senior management, auditors and advisors. Adds that information it received late on Friday has cast significant doubt on the validity of the reported around £770,000 accrued royalty income recorded in the audited accounts for the year ended June 30, and it currently expects that ARI will be removed from the financial 2025 accounts. Expects that this reduces revenue for the year to £3.9 million from the reported £4.6 million, and widens the adjusted Ebitda loss to £1.2 million from around £410,000. Says however that it is confident in SkinBio’s underlying financial health, citing a ‘robust’ £2.9 million cash position as of Friday, and that it ‘believes this is an isolated incident’. However, it also now expects results for the year ending June 30 to be ‘significantly below current market expectations,’ which had anticipated revenue of £6.2 million and adjusted Ebitda of around £700,000. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
